All In Biotech

Drug Trial Radar · NCT06395883

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease - the BOOGIE Study

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jan 1, 2025

Primary completion

Oct 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Diakonhjemmet HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Vestre Viken Hospital Trust; Hormone Laboratory, Aker University Hospital, Oslo, Norway
First posted
May 2, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 25 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment. There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.

Conditions

  • Osteoporosis
  • Osteoporosis, Steroid Induced
  • Inflammatory Rheumatism

Interventions

  • Glucocorticoid EffectDrug

    Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. P1NP level 3 months after glucocorticoid terminationTime frame: september 2024 til december 2025

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Vestre Viken HF, Drammen

    Drammen, Norway · Recruiting

  • Diakonhjemmet hospital

    Oslo, Norway · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.